|
|
 Previous Article | Table of Contents | Next Article 
Autologous Bone Marrow Transplantation for Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS
Theo De Witte,
Anja Van Biezen,
Jo Hermans,
Myriam Labopin,
Volker Runde,
Reuven Or,
Giovanna Meloni,
Salut Brunet Mauri,
Angelo Carella,
Jane Apperley,
Alois Gratwohl, and
Jean-Pierre Laporte for the Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation
From the Department of Hematology, University Hospital Nijmegen, Nijmegen; the Chronic Leukemia Working Party Registry Leiden, Leiden; the Department of Medical Statistics, University of Leiden, Leiden, The Netherlands; the Acute Leukemia Working Party Registry Paris; the Department of Hematology, Hôpital St Antoine Paris, France; the Department of Bone Marrow Transplantation, University Hospital, Essen, Germany; the Department of Bone Marrow Transplantation, Hadassah University, Jerusalem, Israel; the Department of Hematology, University La Sapienza, Roma; the Department of Hematology, Ospedale San Martino, Genova, Italy; the Department of Hematology, Hospital Sante Pau, Barcelona, Spain; the Department of Hematology, Postgraduate School Medical School, London, UK; and the Department of Hematology, Kantonsspittal Basel, Basel, Switzerland.
Intensive chemotherapy followed by autologous bone marrow transplantation (ABMT) may provide an alternative therapy for young patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (sAML) lacking a suitable donor. We report the results for 79 patients with MDS/sAML transplanted with autologous marrow in first complete remission (CR). Within the total group of 79, a cohort of 55 patients for whom the duration of first CR was known were compared with a matched control group of 110 patients with de novo AML. The 2-year survival, disease-free survival (DFS), and relapse rates for the 79 patients transplanted in first CR were 39%, 34%, and 64%, respectively. The relapse risk was greater than 55% for all stages and all disease categories. Patients younger than 40 years had a significantly (P = .04) better DFS (39%) than patients older than 40 years (25%). The DFS at 2 years was 28% for the cohort of 55 patients transplanted for MDS/sAML and 51% for those transplanted for de novo AML (P = .025). Relapse rates were 69% for patients with MDS/sAML and 40% for those with de novo AML (P = .007). ABMT for MDS or secondary leukemia results in a lower DFS when compared with similarly treated patients with de novo AML due to a higher relapse rate. The DFS of 28% for these patients suggests that autotransplantation may be a valuable therapy for this disease. The low treatment-related mortality rate of less than 10% supports the view that sufficient numbers of hematopoietic stem cells are present in patients with MDS to allow adequate repopulation after autologous stem-cell transplantation.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 3853-3857
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Valcarcel, R. Martino, D. Caballero, J. Martin, C. Ferra, J. B. Nieto, A. Sampol, M. T. Bernal, J. L. Pinana, L. Vazquez, et al.
Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival
J. Clin. Oncol.,
February 1, 2008;
26(4):
577 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and A. F. List
Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity
Mayo Clin. Proc.,
May 1, 2005;
80(5):
681 - 698.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. F. List, J. Vardiman, J.-P. J. Issa, and T. M. DeWitte
Myelodysplastic Syndromes
Hematology,
January 1, 2004;
2004(1):
297 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Benesch and H. J. Deeg
Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders
Mayo Clin. Proc.,
August 1, 2003;
78(8):
981 - 990.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho
Myelodysplastic Syndrome
Hematology,
January 1, 2003;
2003(1):
176 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fouillard, M. Labopin, N.-C. Gorin, E. Polge, H. G. Prentice, G. Meloni, J. Reiffers, A. Pigneux, R. Willemze, A. Schattenberg, et al.
Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT)
Blood,
October 16, 2002;
100(9):
3135 - 3140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Castro-Malaspina, R. E. Harris, J. Gajewski, N. Ramsay, R. Collins, B. Dharan, R. King, and H. J. Deeg
Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
Blood,
March 15, 2002;
99(6):
1943 - 1951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cutler and J. H. Antin
Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review
Stem Cells,
February 1, 2001;
19(2):
108 - 117.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. D. Cheson, J. M. Bennett, H. Kantarjian, A. Pinto, C. A. Schiffer, S. D. Nimer, B. Lowenberg, M. Beran, T. M. de Witte, R. M. Stone, et al.
Report of an international working group to standardize response criteria for myelodysplastic syndromes
Blood,
December 1, 2000;
96(12):
3671 - 3674.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nilsson, I. Astrand-Grundstrom, I. Arvidsson, B. Jacobsson, E. Hellstrom-Lindberg, R. Hast, and S. E. W. Jacobsen
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level
Blood,
September 15, 2000;
96(6):
2012 - 2021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Wijermans, M. Lubbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, and A. Ferrant
Low-Dose 5-Aza-2'-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
J. Clin. Oncol.,
March 1, 2000;
18(5):
956 - 956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah
Achievements in Understanding and Treatment of Myelodysplastic Syndromes
Hematology,
January 1, 2000;
2000(1):
110 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Heaney and D. W. Golde
Myelodysplasia
N. Engl. J. Med.,
May 27, 1999;
340(21):
1649 - 1660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Tomasson, I. R. Williams, R. Hasserjian, C. Udomsakdi, S. M. McGrath, J. Schwaller, B. Druker, and D. G. Gilliland
TEL/PDGFbeta R Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor
Blood,
March 1, 1999;
93(5):
1707 - 1714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
